A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With Herpes Zoster Recombinant Subunit (HZ/su) Vaccine in Adults Aged 50 Years and Older
Latest Information Update: 03 Apr 2025
At a glance
- Drugs GSK 137173A (Primary) ; Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GSK
Most Recent Events
- 26 Oct 2024 Status changed from active, no longer recruiting to completed.
- 18 Sep 2024 According to GSK media release, Results from this trial will be submitted for peer-reviewed scientific publication and will be used to support regulatory submissions to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulators.
- 18 Sep 2024 According to GSK media release, data of this trail were presented as a late-breaking abstract at the European Geriatric Medicine Society (EuGMS) Congress in Valencia, Spain (September 18-20th, 2024).